Compare Sanofi SA (SNY) vs iShares TIPS Bond ETF (TIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs iShares TIPS Bond ETF — how do they compare? Sanofi SA trades at $42.7 (market cap $104.06B), while iShares TIPS Bond ETF trades at $106.82. The key difference: Sanofi SA pays a 5.61% dividend while iShares TIPS Bond ETF pays none, and Sanofi SA is trading nearer its 52-week high, iShares TIPS Bond ETF nearer its low. Which is the better fit depends on your goals.
| SNY | TIP | |
|---|---|---|
Market Cap | $104.06B | — |
Sector | Health | Fixed Income |
52-Week High | $52.34 | $112.20 |
52-Week Low | $41.33 | $106.77 |
Enterprise Value | $124.09B | — |
Dividend Yield | 5.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
TIP trades at $107.05 with minimal daily movement (+0.07%), showing stability amid broader market volatility. Technical indicators signal a bearish trend with moving averages and overall momentum favoring sellers. The company has announced upcoming dividends totaling $1.84 per share for H2-2026, providing income appeal. Recent news highlights Treasury market volatility and inflation concerns that may impact bond-related equities.
The stock faces headwinds from bearish technical momentum and macroeconomic uncertainty around interest rates. Dividend payments offer some support, but limited fundamental data availability requires careful monitoring of upcoming financial disclosures for clearer valuation assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About iShares TIPS Bond ETF
TIP is the flagship ETF for U.S. Treasury Inflation-Protected Securities (TIPS). It tracks an index of government bonds whose principal value adjusts based on the Consumer Price Index (CPI), providing a direct hedge against rising inflation.
Read more on TIP →
